Home PipelineMGD009 (B7-H3 x CD3)

Background

MGD009 is a bispecific DART molecule that is designed to target both B7-H3 expressed on tumor cells as well as CD3, which is expressed on normal T cells.

Clinical Development

MGD009 is being evaluated in a Phase 1 clinical trial in patients with B7-H3 positive tumors and in a separate study that combines MGD009 and MGA012 (anti-PD-1 mAb).

Our Rights

MacroGenics retains full worldwide rights to the B7-H3 franchise (including MGD009).

Clinical Trials

Presentations

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close